VRTX - Vertex Pharmaceuticals Incorporated

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
8,930,700
8,930,700
7,574,400
6,205,683
4,162,821
Cost of revenue
1,080,300
1,080,300
904,200
736,300
547,758
Gross profit
7,850,400
7,850,400
6,670,200
5,469,383
3,615,063
Operating expenses
Research development
2,540,300
2,540,300
3,051,100
1,829,537
1,754,540
Selling general and administrative
944,700
944,700
840,100
770,456
658,498
Total operating expenses
3,485,000
3,485,000
3,891,200
2,599,993
2,413,038
Operating income or loss
4,365,400
4,365,400
2,779,000
2,869,390
1,202,025
Interest expense
54,800
54,800
61,500
58,151
58,502
Total other income/expenses net
-222,800
-222,800
8,000
283,320
187,718
Income before tax
4,232,400
4,232,400
2,730,400
3,116,798
1,394,919
Income tax expense
910,400
910,400
388,300
405,151
218,109
Income from continuing operations
3,322,000
3,322,000
2,342,100
2,711,647
1,176,810
Net income
3,322,000
3,322,000
2,342,100
2,711,647
1,176,810
Net income available to common shareholders
3,322,000
3,322,000
2,342,100
2,711,647
1,176,810
Basic EPS
-
12.97
9.09
10.44
4.58
Diluted EPS
-
12.82
9.01
10.29
4.51
Basic average shares
-
256,100
257,700
259,841
256,728
Diluted average shares
-
259,100
259,900
263,396
260,673
EBITDA
-
4,287,200
2,791,900
3,174,949
1,453,421